Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma

Advanced gastro-oesophageal cancer (GEA) treatment has been improved by the introduction of immune checkpoint inhibitors (CPIs), yet identifying predictive biomarkers remains a priority, particularly in patients with a combined positive score (CPS) 

Saved in:
Bibliographic Details
Published in:British journal of cancer 2022-12, Vol.127 (12), p.2198-2206
Main Authors: Cabeza-Segura, Manuel, Gambardella, Valentina, Gimeno-Valiente, Francisco, Carbonell-Asins, Juan Antonio, Alarcón-Molero, Lorena, González-Vilanova, Arturo, Zuñiga-Trejos, Sheila, Rentero-Garrido, Pilar, Villagrasa, Rosana, Gil, Mireia, Durá, Ana, Richart, Paula, Alonso, Noelia, Huerta, Marisol, Roselló, Susana, Roda, Desamparados, Tarazona, Noelia, Martínez-Ciarpaglini, Carolina, Castillo, Josefa, Cervantes, Andrés, Fleitas, Tania
Format: Article
Language:English
Subjects:
Adenocarcinoma
Esophageal cancer
Esophageal Neoplasms - genetics
Esophageal Neoplasms - therapy
Humans
Immune checkpoint inhibitors
Immune response
Immunomodulation
Immunotherapy
Microenvironments
Patient Selection
Patients
Prospective Studies
Retrospective Studies
Transcriptomics
Tumor microenvironment
Tumor Microenvironment - genetics
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Advanced gastro-oesophageal cancer (GEA) treatment has been improved by the introduction of immune checkpoint inhibitors (CPIs), yet identifying predictive biomarkers remains a priority, particularly in patients with a combined positive score (CPS) 
ISSN:0007-0920
1532-1827
DOI:10.1038/s41416-022-02005-z